Spectrum begins Phase 3 DLBCL trial of Zevalin Pharmaceutical Business Review The study will assess overall survival (OS) and progression-free survival (PFS) in patients 60 years and older with DLBCL who achieved remission following R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). |
